Klin Onkol 2003; 16(4): 184-186.
Summary:
Introduction: The role of radiotherapy in the treatment of Hodgkin’s disease has been redefined in recent years. This historically first curative method is nowadays increasingly accepted as a mere complement to combination chemotherapy and some medical oncologists event contemplate about omitting it completely. We summarize the current position of radiotherapy and bring an insight into short-term perspectives.
Results: Early stages – radiotherapy yields excellent overall survival rates, but with relatively high relapse rate. An initial short chemotherapy with involved-field RT is more than an equivalent alternative. Intermediate stages – after chemotherapy, involved-field RT shows no difference in both local control and overall survival in comparison with extended-field RT. Thus, the former approach is preferrable. Advanced stages – the most problematic regarding the indication of radiotherapy. The only doubtless indication is a residual mass after chemotherapy. Elderly patients – prognostically and therapeutically separate subgroup. Radiotherapy has got a key role thanks to its short duration and minimal toxicity.
Conclusion: Radiotherapy remains an important part of the treatment of Hodgkin’s disease except some selected advanced-stage patients.
